Inspection, AERs Prompt Hyland's Teething Tablets Recall
This article was originally published in The Tan Sheet
Executive Summary
Enforcement on Standard Homeopathic Co.'s Hyland's Teething Tablets marks FDA's second action in 18 months against a major U.S. homeopathic firm.
You may also be interested in...
FDA 'Evolving' Homeopathic Drug Enforcement With Risk-Based Approach
Problems stated in a draft guidance where FDA will "prioritize enforcement and regulatory actions" includes products with routes of administration other than oral and topical or intended to be used for the prevention or treatment of serious or life-threatening diseases and conditions.
US FDA Moves Homeopathic Drug Enforcement To Risk-Based Approach
Products with routes of administration other than oral and topical or intended to be used for the prevention or treatment of serious or life-threatening diseases and conditions will be among those prioritized for enforcement and "regulatory actions," draft guidance notes.
US FDA Moves Homeopathic Drug Enforcement To Risk-Based Approach
Products with routes of administration other than oral and topical or intended to be used for the prevention or treatment of serious or life-threatening diseases and conditions will be among those prioritized for enforcement and "regulatory actions," draft guidance notes.